BRAF and melanoma: In melanoma cell lines Δ40p53β has also been found to be elevated in vemurafenib (BRAF inhibitor) resistant cell lines [61], highlighting that Δ40p53 may serve as a potential biomarker to select more individualised and appropriate treatments for melanoma patients.